ARDEN HILLS, Minn., April 29, 2019 (GLOBE NEWSWIRE) -- IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced financial results for its first quarter ended March 31, 2019.
Recent Highlights:
- Quarterly revenue of $30.1 million, an 18.7% increase over the prior-year first quarter
- Gross margin of 29.1%, compared to 33.2% in the prior-year period
- Net income per share of $0.08 versus $0.10 in the 2018 first quarter
- Revenue growth from largest medical customer of 26.6% compared to first quarter 2018
- Announced changes to Board of Directors, effective May 1, 2019
○ Raymond Huggenberger, former Inogen CEO, appointed as a director
○ Michael McKenna retired from his position as Chairman of the Board
○ Philip Smith, a current director, elected Chairman of the Board - Announced leadership promotions
○ Chief Financial Officer Scott Longval assumed additional responsibilities as Chief Operating Officer
○ Michael Geraci named Senior Vice President, Sales and Marketing
○ Dennis Gonsior named Senior Vice President, Global Operations
○ Greg Gruenhagen named Senior Vice President, Quality and Regulatory Affairs
“We were pleased with our first quarter performance and execution, with progress made on each of the priorities we laid out at the start of the year,” said Mark Gorder, President and Chief Executive Officer of IntriCon. “In our Medical business, we continued to benefit from Medtronic’s on-going conversion to its MiniMed 670G system, and we were delighted to secure a new, large medical customer for our proprietary medical coils. In our Hearing Health business, we remain very encouraged by the expanding opportunity we see for our value-based hearing solutions and the relationships we maintain with our current partners. In addition, we are excited to pursue new opportunities for growth spurred by the 2017 legislation that will open a significant new over-the-counter market.
“As we look forward, we will continue to meet the volume demands of our key customers and partners, while pursuing new business opportunities that can best leverage our core competencies and global infrastructure in order to accelerate growth and diversify our revenue base,” concluded Gorder.
First Quarter 2019 Financial Results
For the 2019 first quarter, the company reported net revenue of $30.1 million, up 18.7% from $25.4 million in the comparable prior-year period. The increase was primarily due to year-over-year revenue gains from its diabetes and medical coil markets.
By business line, revenue in IntriCon’s Medical business increased 30.5% in the first quarter of 2019 versus the comparable prior-year period. The gain was primarily driven by the ongoing production of wireless continuous glucose monitoring systems as a result of its long-standing relationship with Medtronic’s Diabetes division. Revenue to this customer increased 26.6% in the first quarter over the comparable prior-year period.
Hearing Health revenue was relatively flat in the first quarter of 2019 compared to the prior-year first quarter. The modest revenue during the quarter was largely due to the impact of a customer’s product cycle in the company’s Indirect-to-End-Consumer channel and measured advertising spend in its Direct-to-End-Consumer channel.
Gross margin in the first quarter of 2019 was 29.1%, down from 33.2% in the prior-year first quarter. Gross margins were constrained by the ongoing validation and qualification expense as well as excess capacity related to the recent manufacturing expansion.
Operating expenses for the first quarter were $7.9 million, compared to $7.1 million in the comparable prior-year period. The increase stemmed from increased advertising investments in our Direct-to-End-Consumer and support costs related to key new business development initiatives.
The company posted net income of approximately $775,000 or $0.08 per diluted share, versus approximately $769,000 or $0.10 per diluted share, for the 2018 first quarter.
2019 Guidance
IntriCon reiterated its previously stated guidance for the full year 2019, which includes revenue of $128 million to $133 million and gross margins of 30.0% to 31.5%. The company continues to anticipate year-over-year revenue growth and gross margin improvement for the full year 2019 with the timing of certain orders related to its largest customer’s on-going global commercial product launch now weighted towards the second half of the year.
Conference Call
IntriCon’s management team will hold a conference call today, Monday, April 29, 2019, beginning at 4:00 p.m. CT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 866-795-7248 for domestic callers or 470-495-9160 for international callers, using conference ID: 2084667. A live and archived webcast will be available on the “Investors” sections of the company’s website at: www.IntriCon.com.
About IntriCon Corporation
Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature and micro-miniature body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better-connected devices. IntriCon has facilities in the United States, Asia, the United Kingdom and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about IntriCon, visit www.intricon.com.
Forward-Looking Statements
Statements made in this release and in IntriCon’s other public filings and releases that are not historical facts or that include forward-looking terminology, including estimates of future results, are “forward-looking statements” within the meaning of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be affected by known and unknown risks, uncertainties and other factors that are beyond IntriCon’s control, and may cause IntriCon’s actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements. These risks, uncertainties and other factors are detailed from time to time in the company’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2018. The company disclaims any intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes available, future developments occur or otherwise.
Investor Contact
Leigh Salvo
(415) 937-5404
investorrelations@intricon.com
| INTRICON CORPORATION MARKET REVENUE (Unaudited) | ||||||||
| FIRST QUARTER | ||||||||
| ($ in 000's) | 2019 | 2018 | Growth | |||||
| Medical | $ | 20,793 | $ | 15,933 | 30.5 | % | ||
| Diabetes | 17,164 | 13,562 | 26.6 | % | ||||
| Other Medical | 3,629 | 2,371 | 53.1 | % | ||||
| Hearing Health | 7,549 | 7,601 | -0.7 | % | ||||
| Value Based Direct-to-End-Consumer | 1,630 | 1,785 | -8.7 | % | ||||
| Value Based Indirect-to-End-Consumer | 2,577 | 2,629 | -2.0 | % | ||||
| Legacy OEM | 3,342 | 3,187 | 4.9 | % | ||||
| Professional Audio Communications | 1,767 | 1,829 | -3.4 | % | ||||
| Total | $ | 30,109 | $ | 25,363 | 18.7 | % | ||
| INTRICON CORPORATION CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited) | |||||||
| Three Months Ended | |||||||
| March 31, 2019 | March 31, 2018 | ||||||
| Revenue, net | $ | 30,109 | $ | 25,363 | |||
| Cost of goods sold | 21,358 | 16,951 | |||||
| Gross profit | 8,751 | 8,412 | |||||
| Operating expenses: | |||||||
| Sales and marketing | 3,536 | 2,840 | |||||
| General and administrative | 3,425 | 3,061 | |||||
| Research and development | 965 | 1,159 | |||||
| Total operating expenses | 7,926 | 7,060 | |||||
| Operating income | 825 | 1,352 | |||||
| Interest income (expense), net | 215 | (188 | ) | ||||
| Other expense, net | (134 | ) | (208 | ) | |||
| Income before income taxes | 906 | 956 | |||||
| Income tax expense | 131 | 187 | |||||
| Net income | $ | 775 | $ | 769 | |||
| Income per share of common stock: | |||||||
| Net income per share, Basic: | $ | 0.09 | $ | 0.11 | |||
| Net income per share, Diluted: | $ | 0.08 | $ | 0.10 | |||
| Average shares outstanding: | |||||||
| Basic | 8,705 | 6,929 | |||||
| Diluted | 9,382 | 7,843 | |||||
| INTRICON CORPORATION CONSOLIDATED CONDENSED BALANCE SHEET (Unaudited) | |||||||
| March 31, | December 31, | ||||||
| 2019 | 2018 | ||||||
| Current assets: | |||||||
| Cash, cash equivalents and restricted cash | $ | 13,190 | $ | 8,047 | |||
| Short-term investments | 16,008 | 38,093 | |||||
| Accounts receivable, less allowance for doubtful accounts of $368 at March 31, 2019 and $807 at December 31, 2018 | 10,493 | 11,479 | |||||
| Inventories | 19,134 | 18,981 | |||||
| Contract assets | 6,320 | 5,624 | |||||
| Other current assets | 1,541 | 2,320 | |||||
| Total current assets | 66,686 | 84,544 | |||||
| Machinery and equipment | 38,202 | 37,161 | |||||
| Less: Accumulated depreciation | 25,941 | 25,429 | |||||
| Net machinery and equipment | 12,261 | 11,732 | |||||
| Goodwill | 10,808 | 10,808 | |||||
| Intangible assets, net | 2,546 | 2,585 | |||||
| Operating lease asset | 5,518 | - | |||||
| Investment in partnerships | 1,324 | 2,091 | |||||
| Long-term investments | 15,228 | - | |||||
| Other assets, net | 6,525 | 3,488 | |||||
| Total assets | $ | 120,896 | $ | 115,248 | |||
| Current liabilities: | |||||||
| Current financing leases | $ | 104 | $ | - | |||
| Current operating leases | 1,700 | - | |||||
| Accounts payable | 12,237 | 13,191 | |||||
| Accrued salaries, wages and commissions | 2,572 | 4,409 | |||||
| Other accrued liabilities | 4,692 | 4,047 | |||||
| Total current liabilities | 21,305 | 21,647 | |||||
| Noncurrent financing leases | 95 | - | |||||
| Noncurrent operating leases | 4,030 | - | |||||
| Other postretirement benefit obligations | 366 | 377 | |||||
| Accrued pension liabilities | 733 | 706 | |||||
| Other long-term liabilities | 1,306 | 544 | |||||
| Total liabilities | 27,835 | 23,274 | |||||
| Commitments and contingencies | |||||||
| Shareholders’ equity: | |||||||
| Common stock, $1.00 par value per share; 20,000 shares authorized; 8,714 and 8,664 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively | 8,714 | 8,664 | |||||
| Additional paid-in capital | 85,131 | 84,999 | |||||
| Retained earnings (accumulated deficit) | 266 | (509 | ) | ||||
| Accumulated other comprehensive loss | (797 | ) | (927 | ) | |||
| Total shareholders' equity | 93,314 | 92,227 | |||||
| Non-controlling interest | (253 | ) | (253 | ) | |||
| Total equity | 93,061 | 91,974 | |||||
| Total liabilities and equity | $ | 120,896 | $ | 115,248 | |||